The companies will also partner on developing ETX2514SUL, a fixed-dose combination of ETX2514 and sulbactam, for the treatment of serious multidrug-resistant infections caused by Acinetobacter baumannii.
According to new data from intelligence provider GBI Research, the flu vaccines market in the Asia-Pacific (APAC) region is set to grow from $1.24 billion in 2015 to more than $1.71 billion in 2022.